TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Halofuginone, Cisplatin
Phytochemical Name Halofuginone (PubChem CID: 400772 )
Anticancer drug Name Cisplatin (PubChem CID: 5702198 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 13
Pair Name Halofuginone, Cisplatin
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression CCND1 hsa595
Up-regulation Expression CDKN1A hsa1026
Down-regulation Phosphorylation MAPK1 hsa5594
Up-regulation Cleavage PARP1 hsa142
Up-regulation Expression PSMD9 hsa5715
Down-regulation Phosphorylation RB1 hsa5925
In Vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
NCI-H460 Lung large cell carcinoma Homo sapiens (Human) CVCL_0459
Result Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways
03. Reference
No. Title Href
1 Halofuginone Sensitizes Lung Cancer Organoids to Cisplatin via Suppressing PI3K/AKT and MAPK Signaling Pathways. Front Cell Dev Biol. 2021 Nov 24;9:773048. doi: 10.3389/fcell.2021.773048. Click
It has been 47151 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP